Immunologic Research

, Volume 43, Issue 1–3, pp 223–242

Partially corrected X-linked severe combined immunodeficiency: long-term problems and treatment options


DOI: 10.1007/s12026-008-8073-6

Cite this article as:
De Ravin, S.S. & Malech, H.L. Immunol Res (2009) 43: 223. doi:10.1007/s12026-008-8073-6


Rapid progress has been made from the identification of the molecular defects causing X-linked severe combined immune deficiency (X-SCID) to the development of cutting-edge therapeutic approaches such as hematopoietic stem cell transplant and gene therapy for XSCID. Successful treatment of XSCID has created a new population of patients, many of whom are now adolescents and young adults and are facing a variety of chronic problems secondary to partial correction of their underlying disease. This review focuses on the clinical challenges facing these patients (and their caregivers) and provides an overview of some of the treatment options available, including gene therapy.


Severe combined immunodeficiency Hematopoietic stem cell transplant Gene therapy Haploidentical T cell recombination excision circles T cell receptor Vbeta spectratype 

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  1. 1.Genetic Immunotherapy, Laboratory of Host DefenseNational Institutes of HealthBethesda USA

Personalised recommendations